Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: long term antigen stability in cancer patient plasma

被引：33

作者：

Cummings, J.

Ranson, M.

Butt, F.

Moore, D.

Dive, C.

机构：

[1] Univ Manchester, Paterson Inst Canc Res, Clin & Expt Pharmacol Grp, Manchester M20 4BX, Lancs, England

[2] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England

来源：

CANCER CHEMOTHERAPY AND PHARMACOLOGY | 2007年 / 60卷 / 06期

关键词：

M65; ELISA; M30; apoptosense; biomarkers; stability; plasma; cancer patients;

D O I：

10.1007/s00280-007-0437-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose M30 and M65 ELISAs are proposed as surrogate biomarkers of tumour cell death in patients and are being applied increasingly in the pharmacodynamic (PD) evaluation of anticancer drugs during clinical trials. In the absence of such data, we have studied the long-term stability of the antigens of both assays in plasma of cancer patients stored at -80 degrees C over 2 years. Results No evidence was detected of degradation in the M65 antigen. However, in a proportion of patients significant increases in levels of M30 antigen were detected Conclusion Plasma samples for M65 analysis can be stored at -80 degrees C for 2 years; however, caution is recommended when considering long-term storage of samples for the M30 assay.

引用

收藏

页码：921 / 924

页数：4

相关论文

共 17 条

[1] Plakin proteins are coordinately cleaved during apoptosis but preferentially through the action of different caspases [J].

Aho, S .

EXPERIMENTAL DERMATOLOGY, 2004, 13 (11) :700-707

[2] Circulating nucleic acids in plasma or serum [J].

Anker, P ;

Lyautey, J ;

Lederrey, C ;

Stroun, M .

CLINICA CHIMICA ACTA, 2001, 313 (1-2) :143-146

[3] Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP [J].

Cummings, J. ;

Ranson, M. ;

LaCasse, E. ;

Ganganagari, J. R. ;

St-Jean, M. ;

Jayson, G. ;

Durkin, J. ;

Dive, C. .

BRITISH JOURNAL OF CANCER, 2006, 95 (01) :42-48

[4] Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP [J].

Cummings, J ;

Ward, TH ;

LaCasse, E ;

Lefebvre, C ;

St-Jean, M ;

Durkin, J ;

Ranson, M ;

Dive, C .

BRITISH JOURNAL OF CANCER, 2005, 92 (03) :532-538

[5] Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma [J].

Deligezer, U ;

Erten, N ;

Akisik, EE ;

Dalay, N .

EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2006, 80 (01) :72-76

[6] Stability of nucleosomal DNA fragments in serum [J].

Holdenrieder, S ;

Mueller, S ;

Stieber, P .

CLINICAL CHEMISTRY, 2005, 51 (06) :1026-1029

[7]

Holdenrieder S, 2001, ANN NY ACAD SCI, V945, P93

[8] Cell-derived microparticles contain caspase 3 in vitro and in vivo [J].

Hussein, MNA ;

Nieuwland, R ;

Hau, CM ;

Evers, LM ;

Meesters, EW ;

Sturk, A .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2005, 3 (05) :888-896

[9] Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles [J].

Kramer, G. ;

Schwarz, S. ;

Hagg, M. ;

Havelka, A. Mandic ;

Linder, S. .

BRITISH JOURNAL OF CANCER, 2006, 94 (11) :1592-1598

[10] Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18 [J].

Kramer, G ;

Erdal, H ;

Mertens, HJMM ;

Nap, M ;

Mauermann, J ;

Steiner, G ;

Marberger, M ;

Bivén, K ;

Shoshan, MC ;

Linder, S .

CANCER RESEARCH, 2004, 64 (05) :1751-1756